Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2003

View Archived Issues

Sunesis and Biogen to discover therapeutics for inflammatory and autoimmune diseases

Type 2 diabetic patients complete first six-month treatment course with Metformin GR

EntreMed licenses thalidomide analogues to Celgene

NDA for Ganite reactivated

Triangle files MAA for emtricitabine

Allos Therapeutics further expands oncology development pipeline

Abbott claims P2X antagonists for pain and urinary incontinence

New inhibitors of IL-12 and/or IL-4 signaling identified at Cell Therapeutics

Merck Frosst develops novel PDE4 inhibitors

Aminoalcohol beta3-adrenoceptor agonists and their use claimed by Fujisawa

Altana researchers investigate novel anti-H. pylori agents

New TGF-beta antagonists for cancer and other uses covered by Lilly patent

Protein kinase inhibitors discovered by Schering scientists

Japanese approval sought for Kissei's mitiglinide

Peginterferon alfa-2a submitted for approval as hepatitis therapy in Japan

Phase II study of RTX in interstitial cystitis commences

Iressa review by the FDA will take more time than anticipated

Merck intends to obtain full ownership of Banyu

ZymoGenetics and Novo Nordisk join forces to develop IL-21

New-generation TTS product cleared for human testing

Promising effects of AEOL-10113 in hyperoxic preterm fetal baboons

Ariad files IND for AP-23573

Infliximab granted priority review by the FDA for fistulizing CD

Moli-1901 granted orphan drug status in Europe

Yamanouchi submits NDA for YM-905 to treat overactive bladder

Muscarinic receptor antagonist with better selectivity for bladder over salivation than tolterodine

Prasterone to be reviewed by EMEA

Advisory committee recommends FDA approval of telithromycin for RTI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...